Pharmaceutical Giant Novartis Challenges India’s Patent Laws, Threatening Delivery of AIDS Drugs to Tens of Thousands


The pharmaceutical industry once again stirs a witches’ brew, reports New Scientist, challenging patent laws that have enabled India to supply AIDS drugs to poor patients worldwide.

India’s generic drugs form the backbone of MSF’s [Medecins Sans Frontieres/Doctors without Borders] AIDS programmes, in which 80,000 people in 30 countries receive treatment.

“We are reaching a quarter of the people who need antiretroviral treatment in sub-Saharan Africa,” says Ivy Mwangi, an MSF doctor. “Rapid scale-up in treatment is only possible with the availability and affordability of generic drugs, most of which are produced in India.”

But Swiss pharma-giant Novartis is whinging that financial hegemony is the only sure road to drug innovation, and that India should not be allowed to provide generics for people who can’t pay $10,000 a year for its drugs.

“If Novartis gets through with its case our lives are at risk,” Monique Wanjala, a woman who has been living with HIV for 13 years, told a news conference in Nairobi. “We want this case dropped,” she said. “If we die because affordable generic drugs aren’t available, where will they sell the drug? If profits are going to be put before peoples’ lives then we have a serious problem.”

FACT:

Mother Jones was founded as a nonprofit in 1976 because we knew corporations and the wealthy wouldn't fund the type of hard-hitting journalism we set out to do.

Today, reader support makes up about two-thirds of our budget, allows us to dig deep on stories that matter, and lets us keep our reporting free for everyone. If you value what you get from Mother Jones, please join us with a tax-deductible donation today so we can keep on doing the type of journalism 2019 demands.

We Recommend

Latest

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate

We have a new comment system! We are now using Coral, from Vox Media, for comments on all new articles. We'd love your feedback.